PE79099A1
(es)
*
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
US6211144B1
(en)
*
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
ES2329220T3
(es)
|
1999-01-06 |
2009-11-24 |
Genentech, Inc. |
Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
|
WO2000040613A1
(en)
|
1999-01-06 |
2000-07-13 |
Genentech, Inc. |
Insulin-like growth factor (igf) i mutant variants
|
DE60005806T2
(de)
|
1999-04-08 |
2004-08-05 |
Genentech, Inc., South San Francisco |
Zusammensetzung auf basis gegensätzlich geladener polypeptide
|
US20040220103A1
(en)
*
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US6746853B1
(en)
|
1999-05-19 |
2004-06-08 |
Xencor, Inc. |
Proteins with insulin-like activity useful in the treatment of diabetes
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US7022674B2
(en)
*
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
US6734162B2
(en)
|
2000-01-24 |
2004-05-11 |
Minimed Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
EP1292324A2
(de)
*
|
2000-05-05 |
2003-03-19 |
Novo Nordisk A/S |
Neuropathien verursacht durch kritischen krankheiten
|
EP1282437B1
(de)
|
2000-05-16 |
2008-03-19 |
Genentech, Inc. |
Behandlung von knorpelerkrankungen
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
AU2002248464A1
(en)
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
ES2298378T3
(es)
|
2001-06-28 |
2008-05-16 |
Novo Nordisk A/S |
Formulacion estable de glp-1 modificado.
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
US20030199445A1
(en)
*
|
2002-02-07 |
2003-10-23 |
Knudsen Lotte Bjerre |
Use of GLP-1 compound for treatment of critically ill patients
|
ES2360182T3
(es)
*
|
2002-05-07 |
2011-06-01 |
Novo Nordisk A/S |
Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
KR101123113B1
(ko)
*
|
2002-07-29 |
2012-03-15 |
쎄라피콘 에스.알.엘. |
코 펩티드 약학 제형
|
ITMI20021684A1
(it)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
Composizione farmaceutica di peptide nasale
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
PL1633391T3
(pl)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
PL3300721T3
(pl)
|
2003-11-20 |
2019-08-30 |
Novo Nordisk A/S |
Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
ES2618028T3
(es)
|
2004-07-19 |
2017-06-20 |
Biocon Limited |
Conjugados insulina-oligómero, formulaciones y usos de éstos.
|
AU2005273968A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
US7597884B2
(en)
*
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP2494983B1
(de)
|
2004-11-12 |
2019-04-24 |
Novo Nordisk A/S |
Stabile formulierung von glp-1
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
BRPI0519468A2
(pt)
|
2004-12-27 |
2009-01-27 |
Silence Therapeutics Ag |
complexos de lipÍdeos revestido e seu uso
|
EP1862174A1
(de)
*
|
2005-03-02 |
2007-12-05 |
Ajinomoto Co., Inc. |
Mittel zur hemmung der insulin-polymer-bildung
|
JP2008542235A
(ja)
*
|
2005-05-25 |
2008-11-27 |
ノボ・ノルデイスク・エー/エス |
安定化ポリペプチド製剤
|
US8097584B2
(en)
*
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20100210506A1
(en)
*
|
2005-10-20 |
2010-08-19 |
Mdrna, Inc. |
Intranasal administration of rapid acting insulin
|
EP1969004B1
(de)
|
2005-12-28 |
2011-08-10 |
Novo Nordisk A/S |
Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
|
US8927015B2
(en)
*
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
CA2649630C
(en)
*
|
2006-04-20 |
2016-04-05 |
Silence Therapeutics Ag |
Lipoplex formulations for specific delivery to vascular endothelium
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
WO2007135117A2
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
US9023793B2
(en)
*
|
2006-09-29 |
2015-05-05 |
Retrophin, Inc. |
Intranasal carbetocin formulations and methods for the treatment of autism
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8114428B2
(en)
*
|
2007-03-08 |
2012-02-14 |
Sbf Synthetic Bone Factory Gmbh |
Methods for manufacturing a composition for treating bone and/or cartilage defects
|
WO2008118387A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Wayne State University |
Erythrocyte atp-release modulators
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
AU2008313248B2
(en)
*
|
2007-10-16 |
2012-04-26 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
PL2910570T3
(pl)
|
2008-03-18 |
2017-06-30 |
Novo Nordisk A/S |
Stabilizowane względem proteaz, acylowane analogi insuliny
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
ES2531657T3
(es)
|
2008-05-01 |
2015-03-18 |
Arecor Limited |
Formulación de una proteína
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP2328607A1
(de)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stabile formulierung eines therapeutischen proteins
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
ES2477552T3
(es)
|
2008-09-08 |
2014-07-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
|
EP2344195A2
(de)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Kombinationstherapie zur behandlung von diabetes und zugehörigen leiden
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
EP2334234A4
(de)
|
2008-09-19 |
2013-03-20 |
Tandem Diabetes Care Inc |
Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
NZ592283A
(en)
|
2008-10-17 |
2012-09-28 |
Sanofi Aventis Deutschland |
Combination of an insulin and the GLP-1 agonist AVE0010
|
WO2010062308A1
(en)
|
2008-10-28 |
2010-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulators of aldehyde dehydrogenase and methods of use thereof
|
JP4959005B2
(ja)
|
2008-10-30 |
2012-06-20 |
ノボ・ノルデイスク・エー/エス |
毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
AU2010208305A1
(en)
|
2009-01-28 |
2011-09-08 |
Smartcells, Inc. |
Synthetic conjugates and uses thereof
|
PE20120583A1
(es)
|
2009-01-28 |
2012-05-19 |
Smartcells Inc |
Sistemas basados en conjugados para entrega farmacologica controlada
|
EP2391216A4
(de)
|
2009-01-28 |
2013-06-19 |
Smartcells Inc |
Exogen ausgelöste stoffe mit verzögerter freisetzung und ihre verwendung
|
CA2750269A1
(en)
|
2009-01-28 |
2010-08-05 |
Smartcells, Inc. |
Crystalline insulin-conjugates
|
MX2011008562A
(es)
|
2009-02-12 |
2011-09-09 |
Proyecto Biomedicina Cima Sl |
Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabolicas.
|
AU2010217760B2
(en)
|
2009-02-27 |
2015-04-09 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
US9250106B2
(en)
|
2009-02-27 |
2016-02-02 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
WO2010107520A1
(en)
|
2009-03-20 |
2010-09-23 |
Smartcells, Inc. |
Soluble non-depot insulin conjugates and uses thereof
|
WO2010107519A1
(en)
|
2009-03-20 |
2010-09-23 |
Smartcells, Inc. |
Terminally-functionalized conjugates and uses thereof
|
HUE027239T2
(en)
*
|
2009-06-26 |
2016-10-28 |
Novo Nordisk As |
Preparation containing insulin, nicotinamide and arginine
|
WO2011014704A2
(en)
|
2009-07-30 |
2011-02-03 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
MX2012005184A
(es)
|
2009-11-13 |
2012-06-08 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1 y metionina.
|
MX2012005186A
(es)
|
2009-11-13 |
2012-06-08 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina.
|
KR20210033559A
(ko)
|
2009-11-27 |
2021-03-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
CN101912600B
(zh)
*
|
2010-01-11 |
2014-01-29 |
杨国汉 |
改善胰岛素在溶液中稳定性的方法
|
US9186392B2
(en)
|
2010-05-05 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
WO2012015692A2
(en)
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Recombinantly expressed insulin polypeptides and uses thereof
|
EP2598522A4
(de)
|
2010-07-28 |
2014-11-12 |
Smartcells Inc |
Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
|
WO2012015681A2
(en)
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
DK2632478T3
(da)
|
2010-10-27 |
2019-10-07 |
Novo Nordisk As |
Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
CN102188367B
(zh)
*
|
2011-01-05 |
2012-11-07 |
山东新时代药业有限公司 |
一种甘精胰岛素注射液及其制备方法
|
US10457659B2
(en)
|
2011-04-29 |
2019-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130345113A1
(en)
*
|
2011-07-13 |
2013-12-26 |
Ronald E. Strohbehn |
Method of Use of Activated Functional Proteins to Improve Animal Health
|
CA2841552C
(en)
|
2011-07-15 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
SI2750699T1
(sl)
|
2011-08-29 |
2015-11-30 |
Sanofi-Aventis Deutschland Gmbh |
Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
EP2773331B1
(de)
*
|
2011-10-31 |
2016-02-10 |
Xeris Pharmaceuticals, Inc. |
Formulierungen zur behandlung von diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2849755A1
(de)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9555186B2
(en)
|
2012-06-05 |
2017-01-31 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
JP6735561B2
(ja)
|
2012-12-03 |
2020-08-05 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体
|
BR112015011179A8
(pt)
|
2012-12-19 |
2019-10-01 |
Wockhardt Ltd |
composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
|
CA2889162A1
(en)
|
2012-12-26 |
2014-07-03 |
Wockhardt Limited |
Pharmaceutical composition
|
TWI780236B
(zh)
*
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US10201656B2
(en)
|
2013-03-13 |
2019-02-12 |
Tandem Diabetes Care, Inc. |
Simplified insulin pump for type II diabetics
|
EP2970124B1
(de)
|
2013-03-14 |
2019-05-22 |
The Board of Trustees of the Leland Stanford Junior University |
Mitochondriale aldehyd-dehydrogenase-2-modulatoren und verfahren zur verwendung davon
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
US9492608B2
(en)
|
2013-03-15 |
2016-11-15 |
Tandem Diabetes Care, Inc. |
Method and device utilizing insulin delivery protocols
|
AU2014247167B2
(en)
|
2013-04-03 |
2018-11-22 |
Sanofi |
Treatment of diabetes mellitus by long–acting formulations of insulins
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
WO2015008169A2
(en)
*
|
2013-07-04 |
2015-01-22 |
Insuline Medical Ltd. |
Device, system and method for delivery of a long-acting drug
|
EP3052134B1
(de)
|
2013-10-04 |
2021-05-05 |
Merck Sharp & Dohme Corp. |
Auf glucose reagierende insulinkonjugate
|
AR098168A1
(es)
|
2013-10-25 |
2016-05-04 |
Sanofi Sa |
Formulación estable de insulina glulisina
|
EP3091995B1
(de)
|
2014-01-09 |
2024-03-20 |
Sanofi |
Stabilisierte pharmazeutische formulierungen von insulin aspart
|
US9895424B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CN114939156A
(zh)
|
2014-01-09 |
2022-08-26 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|
JP6944780B2
(ja)
*
|
2014-01-13 |
2021-10-06 |
サーマリン インコーポレイテッド |
速効型インスリン製剤及び医薬送達システム
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN105535942B
(zh)
*
|
2016-01-28 |
2017-07-28 |
通化东宝药业股份有限公司 |
一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
|
EP3419649A1
(de)
*
|
2016-02-25 |
2019-01-02 |
Wockhardt Limited |
Pharmazeutische zusammensetzung aus insulinglargin und aminosäuren
|
CA3022202A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
CN110087674B
(zh)
|
2016-12-16 |
2023-01-03 |
诺和诺德股份有限公司 |
含胰岛素的药物组合物
|
SG11202003754YA
(en)
|
2017-05-16 |
2020-05-28 |
Bhamis Research Laboratory Pvt Ltd |
High concentration protein formulations with reduced viscosity
|
PE20211202A1
(es)
|
2017-08-24 |
2021-07-05 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
US11413352B2
(en)
|
2017-12-18 |
2022-08-16 |
Merck, Sharp & Dohme LLC |
Conjugate based systems for controlled insulin delivery
|
EP3727424A4
(de)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Konjugatbasierte systeme für kontrollierte insulinfreisetzung
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
CN110063932A
(zh)
*
|
2019-04-12 |
2019-07-30 |
浙江大学 |
一种多肽蛋白类药物的缓释组合物制剂及其制备方法
|
EP4106724A1
(de)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Glp-1-zusammensetzungen und verwendungen davon
|
CR20220555A
(es)
|
2020-03-31 |
2023-01-23 |
Protomer Tech Inc |
Conjugados para reactividad selectiva a dioles vecinales
|
AU2021382599A1
(en)
|
2020-11-19 |
2023-06-22 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and insulin analogs
|
WO2023017537A1
(en)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Oral algal oil based gastro-intestinal tract permeable peptide composition
|
US20230374045A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|